New & Noteworthy!

ACC Rockies Chapter Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit: ACC Rockies Chapter Meeting 2025

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • Clinical Practice Algorithms For Wolff-Parkinson-White Pattern in Pediatric Patients
    In 1930, Drs. Louis Wolff, John Parkinson, and Paul White characterized a condition that was described as an abnormally short PR interval, bundle branch block, and episodes of tachycardia and/or atrial fibrillation, which was subsequently named Wolff-Parkinson-White (WPW) syndrome.
  • Study Assesses Coronary Sinus Reducer Implantation in RA
    Coronary sinus reducer (CSR) implantation may be safe and feasible, with promising antianginal efficacy in patients with refractory angina (RA), according to a meta-analysis published Aug. 11 in JACC: Cardiovascular Interventions.
  • New Proposed Values For PCI Codes | 2026 Medicare PFS Proposed Rule
    The Centers for Medicare and Medicaid Services (CMS) has proposed updated values to the PCI family of codes in the proposed 2026 Medicare Physician Fee Schedule (PFS), following revisions made by the CPT Editorial Panel in February 2024 and revaluation by the American Medical Association Relative Value Scale Update Committee (RUC) in April 2024.
  • Early Administration of Heparin at First Medical Contact for PPCI of STEMI Patients
    The goal of the HELP-PCI trial was to determine the efficacy and safety of administering unfractionated heparin at first medical contact versus during cardiac catheterization only in patients with ST-segment elevation myocardial infarction (STEMI).
  • HELIOS-B Analyses: Vutrisiran Significantly Affects Biomarkers, Echocardiographic Parameters
    Two post-hoc analyses of the HELIOS-B trial published Aug. 4 in JACC found that vutrisiran had significant effect on both biomarkers like NT-proBNP and troponin I levels and echocardiographic measures of biventricular systolic and diastolic function in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM). Furthermore, both these biomarkers and echocardiographic measures provide critical prognostic information.